Photo=FILA Golf Luxury brands are increasingly extending automotive engineering and design into performance apparel as sportswear companies seek higher-margin opportunities in premium markets. For U.S. investors tracking global sportswear competition, FILA Golf’s new partnership with Bugatti highlights how brands are using luxury positioning, technical materials and local distribution networks to differentiate products in China’s high-end golf market. FILA Golf, owned

Photo=MISSHA JAPAN South Korean beauty brands are increasingly adapting products to local consumer preferences as competition intensifies in Japan’s cosmetics market. For U.S. beauty companies and investors tracking the global expansion of Korean cosmetics, MISSHA’s latest launch highlights a strategy built around local expertise, customized shades and influencer-led marketing rather than relying solely on the popularity of Korean beauty products.

The global video game industry is increasingly rewarding publishers that can sustain blockbuster franchises while controlling development costs, a divide expected to shape South Korea’s third-quarter earnings season. For U.S. investors evaluating Asian gaming stocks and competition in the global market, forecasts released October 27 point to sharply different trajectories: Krafton is poised for strong revenue growth, NCSoft is expected

Photo=Motionelements South Korea’s rapid cash outflows after payday highlight the financial pressures facing younger consumers in a country where household spending, savings and debt management are increasingly important to banks and consumer-focused businesses. For U.S. investors tracking Asian consumer trends, the data offer a glimpse into how income is distributed across generations and how little cash some younger workers retain

(Photo=Eli Lilly) The global boom in obesity drugs is exposing a divide in how governments control the cost of medicine. In Japan, public health insurance helps regulate the price of Eli Lilly's Mounjaro. In neighboring South Korea, patients pay substantially more for the American company's drug, and authorities are preventing them from bringing home cheaper supplies legally purchased abroad. A